Oncolytics Biotech Inc. (TSE:ONC – Get Free Report)’s stock price crossed above its 200-day moving average during trading on Friday . The stock has a 200-day moving average of C$14.90 and traded as high as C$14.90. Oncolytics Biotech shares last traded at C$14.90, with a volume of 280 shares traded.
Oncolytics Biotech Stock Performance
The company has a debt-to-equity ratio of 14.58, a quick ratio of 8.86 and a current ratio of 2.88. The firm has a market capitalization of C$1.50 billion, a price-to-earnings ratio of -40.27 and a beta of 0.80. The firm’s 50-day moving average price is C$14.90 and its two-hundred day moving average price is C$14.90.
About Oncolytics Biotech
Oncolytics Biotech Inc, a clinical-stage biopharmaceutical company, focuses on the discovery and development of pharmaceutical products for the treatment of cancer. The company is developing pelareorep, an intravenously delivered immunotherapeutic agent, which is in phase 3 clinical trial for the treatment of hormone receptor-positive / human epidermal growth factor 2-negative metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma. It has a co-development agreement with Merck KGaA and Pfizer Inc to co-develop pelareorep, as well as with Roche Holding AG.
Read More
- Five stocks we like better than Oncolytics Biotech
- What to Expect From Q2 Earnings as Tech Strength Broadens
- Viasat’s Orbiting Profits: Space Force Jackpot?
- Robinhood Wants a Bigger Role in IPOs—Here’s Why It Matters
- Alphabet’s Most Overlooked Division Just Had a Big Week
Receive News & Ratings for Oncolytics Biotech Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Oncolytics Biotech and related companies with MarketBeat.com's FREE daily email newsletter.
